76 Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview

Bokic, T. (Graz); Storr, M. (Starnberg); Schicho, R. (Graz)

1 Downregulation of BDNF Expression by PKC and by TNF-α in Human Endothelial Cells

Xu, H. (Wuhan/Mainz); Czerwinski, P.; Xia, N.; Förstermann, U.; Li, H. (Mainz)

11 Synergistic Interaction of Retigabine with Levetiracetam in the Mouse Maximal Electroshock-Induced Seizure Model: A Type II Isobolographic Analysis


16 Regulatory Roles of Endogenous Mitogen-Activated Protein Kinases and Tyrosine Kinases in the Pacemaker Activity of Colonic Intestinal Cells of Cajal


25 Ginsenoside Rg1 Ameliorates Motor Function in an Animal Model of Parkinson’s Disease

Jiang, W. (Jinzhou); Wang, Z. (Dalian); Jiang, Y.; Lu, M.; Li, X. (Jinzhou)

32 Ginsenoside Rb2 Attenuates UV-B Radiation-Induced Reactive Oxygen Species and Matrix Metalloproteinase-2 through Upregulation of Antioxidant Components in Human Dermal Fibroblasts

Oh, S.-J.; Kim, K.; Lim, C.-J. (Chuncheon)

44 Protein Profiling of Women with Spontaneous Preterm Birth


49 Determination of Caudatin in Rat Plasma by UPLC-MS/MS: Application to a Preclinical Pharmacokinetic Study

Zhu, Q.; Hu, Y.; Shan, Y.; Wang, Y.; Wu, X.; Mao, B.; Ge, R.-S. (Wenzhou)

55 CYP3A4*1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients


61 Nicotine-Induced Modulation of the Cholinergic Twitch Response in the Ileum of Guinea Pig

Donnerer, J.; Liebmann, I. (Graz)

68 Multiple-Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Subjects: A Comparison of Controlled-Release Sarpogrelate and Immediate-Release Sarpogrelate


86 High-Concentration Piperine: Capsaicin-Sensitive and -Insensitive Effects on Isolated Organs

Bencsik, T.; Sandor, Z.; Bartho, L. (Pécs)

90 Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment

Hira, D. (Otsu); Chisaki, Y. (Kyoto); Noda, S.; Araki, H.; Uzu, T.; Maegawa, H. (Otsu); Yano, Y. (Kyoto); Morita, S.; Terada, T. (Otsu)

41 Serenoa repens as an Endocrine Disruptor in a 10-Year-Old Young Girl: A New Case Report

Morabito, P.; Miroddi, M.; Giovinazzo, S.; Spina, E.; Calapai, G. (Messina)
The Challenge of Drug-Induced Liver Injury (DILI) / Challenges and Management of Liver Cirrhosis

Editors
A.L. Gerbes
H.W. Jaeschke
J. Bosch
M. Pinzani
F. Wong

Contents

• Preface: Gerbes, A.L.; Jaeschke, H.

Understanding the Problem of DILI
• Drug-Induced Liver Injury is a Major Risk for New Drugs: Seeff, L.B.
• Acetaminophen: Dose-Dependent Drug Hepatotoxicity and Acute Liver Failure in Patients: Jaeschke, H.
• How to Diagnose and Exclude Drug-Induced Liver Injury: Watkins, P.B.
• Preventing Drug-Induced Liver Injury: How Useful Are Animal Models? Ballet, F.

Dealing with DILI in Drug Development
• Drug-Induced Liver Injury and Individual Cell Models: Benesic, A.; Gerbes, A.L.

Fibrosis: Pathophysiology, Diagnosis and Treatment
• Pathophysiology of Liver Fibrosis: Pinzani, M.
• Noninvasive Assessment of Liver Fibrosis: Castera, L.
• Hepatic Fibrosis: Emerging Therapies: Friedman, S.L.

Portal Hypertension and Complications
• Pathophysiology and a Rational Basis of Therapy: Gracia-Sancho, J.; Maeso-Díaz, R.; Bosch, J.
• Clinical Evaluation and Prognosis: Hernández-Gea, V.; Berzigotti, A.
• Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt – When and How? Abraldes, J.G.; Tandon, P.

Kidney Problems in Cirrhosis
• Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis: Solà, E.; Ginés, P.
• Definition and Diagnosis of Acute Kidney Injury in Cirrhosis: Wong, F.
• The Treatment of Hepatorenal Syndrome: Cavallin, M.; Fasolato, S.; Marenco, S.; Piano, S.; Tonon, M.; Angeli, P.

Cognitive Dysfunction in Cirrhosis
• The Clinical Relevance of Minimal Hepatic Encephalopathy – A Critical Look: Weissenborn, K.
• Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy: Direkze, S.; Jalan, R.

Bacterial Infections in Cirrhosis
• Infection as a Trigger for Portal Hypertension: Steib, C.J.; Schewe, J.; Gerbes, A.L.
• Role of Infections in Acute-on-Chronic Liver Failure: Moreau, R.
• Treatment of Spontaneous Bacterial Peritonitis: Salerno, F.; La Mura, V.

Hepatocellular Carcinoma
• Molecular Profiling and Research of Therapeutic Targets: Rizvi, S.; Gores, G.J.
• Systemic Treatment: Expecting Further Success: Gazzola, A.; Reig, M.; Di Donato, R.; Bruix, J.

Practical Issues – Therapy in Patients with Cirrhosis
• Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis: Boettler, T.; Thimme, R.
• Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis: Bailly, F.; Pradat, P.; Virlogeux, V.; Zoulim, F.

The easiest way to order: www.karger.com/ddi
Pharmacology

International Journal of Experimental and Clinical Pharmacology

Founded 1959 as 'Medicina Experimentalis', continued 1965–1967 as 'Medicina et Pharmacologia Experimentalis'

Editors
J. Donnerer, Graz
K. Takeuchi, Kyoto
K.E. Vrana, Hershey, Pa.

Editorial Board
C. Antoniou, Athens
J. Ahrens, Hannover
L.Z. Benet, San Francisco, Calif.
M.L. Billingsley, Hershey, Pa.
A. Breckenridge, London
K.K. Burkhart, Silver Spring, Md.
G. Coruzzi, Parma
S. Dhein, Leipzig
T.L. Goodfriend, Madison, Wisc.
L.S. Harris, Richmond, Va.
M. Hirafuji, Ishikari-Tobetsu
M.D. Hollenberg, Calgary, Alta.
M. Inui, Yamaguchi
K. Ishii, Yamagata
C. Joukhadar, Boston, Mass.

Y. Kamisaki, Osaka
N. Kaplowitz, Los Angeles, Calif.
A. Kawabata, Osaka
A. Levitzki, Jerusalem
B.R. Lucchesi, Ann Arbor, Mich.
W.E. Müller, Frankfurt am Main
N.H. Neff, Columbus, Ohio
J.P. O'Callaghan,
Morgantown, W.Va.
K. Pennypacker, Tampa, Fla.
S. Saha, Kansas City, Mo.
C. Scarpignato, Nantes
C.D. Smith, Charlestown, S.C.
E. Taira, Iwate
C. Zeng, Chongqing City
Submission
The journal publishes articles dealing with all aspects of experimental and clinical pharmacology. Papers dealing with mechanistic aspects at a molecular level are particularly encouraged. They can be full articles as well as short communications of investigative findings. Reviews, comments and perspective notes on timely topics are specifically welcome. Reviews in which a specific field is reviewed through an extensive literature survey. An Abstract is required and should be divided into Background, Summary and Key Messages. Review Articles should consist of a maximum of 4,000 words. We consider investigations dealing with biological extracts or with phytopharmaceutical preparations as outside the scope of our journal. Only papers written in English are considered and should be submitted using the online submission website at:

www.karger.com/pha
or sent as e-mail attachment (the preferred word-processing package is MS-Word) to the Editorial Office:

pha@karger.com
Prof. J. Donnerer
S. Karger AG
Editorial Office 'Pharmacology'
P.O. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1356
Fax +41 61 306 1434

Names, postal and e-mail addresses of 4 experts in the appropriate area of research should accompany each manuscript. Referees suggested should not be from the same institution or be research collaborators of the author(s).

Conditions
All manuscripts are subject to editorial review. Manuscripts which do not properly consider ethical issues for humans or animals will not be accepted for publication. In the 'Methods' section, it is recommended to mention the approval given by the responsible authorities. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers necessitate prior explanation by chemical name or drug names: Authors are requested to use International non-proprietary names definitely recommended or, if no final recommendation has been made, proposed by the World Health Organisation (WHO). The use of laboratory code numbers necessitates prior explanation by chemical name or structural formula.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (not size 180 × 223 mm) or provide crop marks. Each illustration must be labeled with its number and the first author's name. The final resolution for b/w half-tone and color illustrations must be 300 dpi after scaling. Line drawings require 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (for detailed instructions, see http://www.karger.com/pha).

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid redundant color illustrations per page can be integrated within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The names of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the author(s). Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.
Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits your manuscript on your behalf to PubMed Central (PMCID) immediately upon publication. It usually receives a PMCID within approximately a month and will appear in PMC after 12 months. For those selecting our premium Author’s Choice™ service, the usual embargo will be overridden, accelerating the accessibility of your work.

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges
There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a page is equal to approx. 14 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order form and price list is sent with the pdf proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

For over 40 years the Karger Gazette has been distributed to a growing audience worldwide. Published in newspaper format, it highlights advances in biomedicine and clinical practice, introduces personalities, portrays research institutes and chronicles milestones in the history of Karger Publishers in a lively and readable style.

The new anniversary issue celebrates Karger’s 125 years as a medical publisher. It explores the STM publishing business in the digital age, offers short portraits of Karger’s journal and book series editors, and includes interviews with three renowned scientists who talk about their careers and how they define progress.

Register for a free print subscription or read it online at www.karger.com/gazette
Contents

See the journal website for contents
Mistletoe: From Mythology to Evidence-Based Medicine

Editors
Kurt S. Zänker
Srini V. Kaveri

Since ancient times the mistletoe plant has been used for healing diseases. Today mistletoe extract therapy is among the most thoroughly studied complementary treatments in Europe. Several studies and meta-analyses have shown it to be beneficial for cancer patients in terms of survival, improved quality of life and minimised side effects of cancer chemotherapy.

This book gives an overview of the research on mistletoe therapy from antiquity to the present. Topics discussed include the cultural and medical history of mistletoe, the diversity of the plant’s molecular constituents, and its anticancer activities including cytotoxicity and immunomodulation. A timeline of the development of mistletoe research is presented. Special attention is given to the application of mistletoe extracts as a supportive treatment in glioblastoma, after cancer surgery and in cancer-related fatigue.

Contents

- Foreword: Chan, S.H.H.
- Preface: Zänker, K.S.; Kaveri, S.V.
- Mistletoe through Cultural and Medical History: The All-Healing Plant Proves to Be a Cancer-Specific Remedy: Ramm, H.
- Chemical Constituents of *Viscum album* L.: Implications for the Pharmaceutical Preparation of Mistletoe: Urech, K.; Baumgartner, S.
- The Anti-Cancer Activity of Mistletoe Preparations, as Related to Their Polyphenolic Profiles: Schramm, H.M.
- From Berlin and Witten to Southampton and Hamburg: 25 Years of Mistletoe Research Cooperation: Schumacher, U.; Pfüller, U.
- Cancer Surgery and Supportive Mistletoe Therapy: From Skepticism to Randomised Clinical Trials: Galun, D.; Tröger, W.; Milicevic, M.
- Dissecting the Anti-Inflammatory Effects of *Viscum album*: Inhibition of Cytokine-Induced Expression of Cyclo-Oxygenase-2 and Secretion of Prostaglandin E2: Elluru, S.B.; Saha, C.; Hedge, P.; Friboulet, A.; Bayry, J.; Kaveri, S.V.
- Dancing with the Devil: Cancer-Related Fatigue, from Inflammation to Treatment Options: Zänker, K.S.

Index

Author Index
Subject Index
Quantitative EEG, a technique for topographic display and analysis of brain electrophysiological data, has been proposed for use in the diagnosis of various neurological and psychiatric disorders. In this special issue the pathophysiology, diagnosis and treatment for neurological and psychiatric disorders using quantitative EEG are described. Event-related synchronization and desynchronization of high-frequency EEG activity during a visual go/no-go paradigm are discussed in detail. Furthermore, integrating different aspects of resting brain activity, electroencephalographic findings in idiopathic REM sleep behavior disorders as well as the quantitative EEG analysis in patients with chronic hepatitis C treated with interferon-alpha are reviewed. Last but not least, topographic analysis of electroencephalographic changes during photic driving responses in patients with migraine and the emotional information processing related to the psychosomatic state evaluated by EEG and ELORETA are presented. This special issue is essential reading for neuropharmacologists, neurologists, physiologists and psychiatrists interested in quantitative EEG.

Contents

• Preface: Kinoshita, T.; Hirata, K.
• Event-Related Synchronization and Desynchronization of High-Frequency Electroencephalographic Activity during a Visual Go/No-Go Paradigm: Iijima, M.; Mase, R.; Osawa, M.; Shimizu, S.; Uchiyama, S.
• Electroencephalographic Finding in Idiopathic REM Sleep Behavior Disorder: Inoue, Y.; Sasai, T.; Hirata, K.
• Quantitative Electroencephalographic Analysis in Patients with Chronic Hepatitis C Treated with Interferon-α: A Review Article: Morita, A.
• Topographic Analysis of Electroencephalographic Changes during Photic Driving Responses in Patients with Migraine: Takashima, R.; Tanaka, H.; Kimoto, K.; Watanabe, Y.; Hirata, K.

Author Index / Subject Index

The easiest way to order: www.karger.com/nps
We are entering a new and exciting era of microbiological study and application. Recent advances in the now established disciplines of genomics, proteomics and bioinformatics, together with extensive cooperation between academic and industrial concerns have brought about an integration of basic and applied microbiology as never before. The Journal of Molecular Microbiology and Biotechnology (JMMB) aims to reflect this development by publishing original research papers from all areas of microbiology and biotechnology. It also features written symposia on selected topics, timely reviews and minireviews. Theoretical approaches and descriptions of novel, microbiologically relevant software is also considered. Contributions and ideas from large segments of the scientific community are welcome to make JMMB a viable, much-needed and up-and-coming forum for current basic and applied microbiological research.

Selected contributions
• Microcompartments and Protein Machines in Prokaryotes: Saier Jr., M.H. (La Jolla, Calif.)
• Control of Protein Function through Regulated Protein Degradation: Biotechnological and Biomedical Applications: Nagpal, J.; Tan, J.L.; Truscott, K.N.; Heras, B.; Dougan, D.A. (Melbourne, Vic.)
• Molecular Motors in Bacterial Secretion: Pení, A.; Arechaga, I. (Santander)
• Mechanisms of Cholesterol-Lowering Effects of Lactobacilli and Bifidobacteria Strains as Potential Probiotics with Their bsh Gene Analysis: Öner, Ö.; Aslim, B. (Ankara); Aydaş, S.B. (Gölbaşı/Ankara)
• Evidence for the Involvement of Intracellular Ca²⁺ Ions in the Elicitation Mechanism of Bacillus licheniformis: Reffatti, P.F.; Roy, J.; Odell, M.; Keshavarz, T. (London)
• Arxula adeninivorans Recombinant Urate Oxidase and Its Application in the Production of Food with Low Uric Acid Content: Trautwein-Schult, A.; Jankowska, D. (Gatersleben); Cordes, A.; Hoferichter, P.; Klein, C.; (Wolfenbüttel); Matros, A.; Mock, H.-P. (Gatersleben); Baronian, K. (Christchurch); Bode, R. (Grefrath); Kunze, G. (Gatersleben)
• Membranous Organelles in Bacteria: Saier Jr., M.H. (San Diego, Calif.); Bogdanov, M.V. (Houston, Tex.)
• The Bacterial Magnetosome: A Unique Prokaryotic Organelle: Lower, B.H. (Columbus, Ohio); Bazylnski, D.A. (Las Vegas, Nev.)
• The Coevolutionary Roots of Biochemistry and Cellular Organization Challenge the RNA World Paradigm: Caetano-Anollès, G.; Seufferheld, M.J. (Urbana, Ill.)
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Editors
Gerhard Rogler
Hans Herfarth
Toshifumi Hibi
Ole Haagen Nielsen

The introduction of anti-tumor necrosis factor (TNF) antibodies into the treatment of patients with IBD about fifteen years ago has dramatically improved the quality of life for patients with severe Crohn’s disease and ulcerative colitis. Despite the fact that this therapeutic approach has been around for quite some time, there has been no comprehensive overview to date. The book at hand aims to amend this shortcoming, presenting for the first time a thorough overview on TNF action, mechanisms of anti-TNF therapy, treatment strategies, side effects, monitoring, biosimilars and related issues. Including up-to-the-art information and research results, this publication will be a valuable source of information and guide clinicians to the optimal treatment decision, improving the quality of life of patients with IBD. Moreover, rheumatologists or even dermatologists might also find this book of interest.

Contents

- Preface: Rogler, G. et al.
- Physiological Role of TNF in Mucosal Immunology
  - The Effect of TNF on the Regulation of Epithelial Function in IBD: Tsuchiya, K.
  - Physiological Role of TNF in Mucosal Immunology: Regulation of Macrophage/Dendritic Cell Function: Rivollier, A. et al.
  - Physiological Role of TNF in Mucosal Immunology: Regulation of T-Cell Function: Scharl, M.
- Pathophysiological Role of TNF in IBD
  - Pathophysiological Role of TNF in IBD: TNF and Its Impact on Barrier Function: Schumann, M.; Kühnel, A.
  - Pathophysiological Role of TNF in IBD: TNF and Its Effect on Innate Immune Defense: Scharl, M.
  - TNF and Its Impact on Adaptive Immune Mechanisms and Chronic Inflammation: Siegmund, B.
- Mechanism of Action of Anti-TNF Antibodies
  - Binding of Membrane-Bound TNF: Atrey, R. et al.
  - Apoptosis of T Cells and Monocytes: Kucharczyk, T.
  - Neutralisation of Soluble TNF: Dreesen, E.; Gilis, A.

General Treatment Considerations

- Recommended Screening Procedures before Treatment with Anti-TNF Agents: Maaser, C.
- The Risk of Formation of Neutralizing Antibodies: Clark, J.; Sakuraba, A.
- TNF Antagonist trough Concentrations and Treatment Efficacy in IBD: Vande Casteele, N.

Biosimilars

- What Is a Biosimilar? Neri, D.
- Is Extrapolation of Safety and Efficacy Data Possible? Ainsworth, M.
- Potential Concerns and Questions: Rogler, G.

Side Effects of Anti-TNF Therapy

- Psoriasis-Like Lesions and Skin Reactions: Herfarth, H.H. et al.
- The Elicitation of Rheumatic Symptoms at Vascular Sites: Geyer, M.; Müller-Ladner, U.
- Serum Reaction, Lupus-Like Syndrome: Schnitzer, F.

Risks of Anti-TNF Therapy

- Risk of Non-Hematologic Malignancy with Anti-TNF Therapy in IBD: Jain, A. et al.
- Risk of Lymphoma: Nagahori, M.; Watanabe, M.
- Risk of Serious Infection: Naganuma, M.
- Risk of Post-Operative Infections with Anti-TNF Therapy: Cohen, B.L.

Anti-TNF Therapy in Crohn’s Disease

- The ‘Ideal’ Anti-TNF Patient: Indications for Anti-TNF Therapy in Crohn’s Disease: Tran Minh, M.-L. et al.
- Predictor of Treatment Response: Tanaka, H.; Motoya, S.
- Step-Up or Top-Down: Combination with Immunosuppression or Not? Barthel, C.; Stange, E.F.

Anti-TNF Therapy in Ulcerative Colitis

- The ‘Ideal’ Anti-TNF Patient: Indications for Anti-TNF Therapy in Ulcerative Colitis: Hisamatsu, T.
- Predictors of the Treatment Response: Kim, H.J.
- What Is the Right Dosage? Michetti, P.

Anti-TNF Therapy in Special IBD Situations

- Fistulizing and Stricturing Crohn’s Disease: Schumann, M.; Kühnel, A.
- Step-Up or Top-Down: Combination with Immunosuppression or Not? Barthel, C.; Stange, E.F.

Anti-TNF Therapy in IBD: Indications for Anti-TNF Therapy

- The ‘Ideal’ Anti-TNF Patient: Indications for Anti-TNF Therapy in IBD: Hisamatsu, T.
- Predictors of the Treatment Response: Kim, H.J.
- What Is the Right Dosage? Michetti, P.

When and How to Stop Anti-TNF Treatment in IBD

- When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping Treatment: Louis, E.
- Treatment Options after Anti-TNF Failure: Kobayashi, T.